Expertise in
26
conditions

Dr. John M. Mccarty

Oncology | Hematology | Transplant Surgery
Mcv Associated Physicians
1300 E Marshall St, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
36 Years of Experience
Expertise in
26
conditions
Mcv Associated Physicians
1300 E Marshall St, 
Richmond, VA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Mccarty is an Oncologist and a Hematologist in Richmond, Virginia. Dr. Mccarty has been practicing medicine for over 36 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Colonoscopy. Dr. Mccarty is currently accepting new patients.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Transplant Surgery
Licenses
Internal Medicine in VA
Hospital Affiliations
Medical College Of Virginia Hospitals
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
HealthKeepers
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MCV ASSOCIATED PHYSICIANS
1300 E Marshall St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Enrollment Status: Recruiting
Publish Date: September 26, 2025
Intervention Type: Biological
Study Drugs: Lisocabtagene Maraleucel, Ibrutinib
Study Phase: Phase 1/Phase 2
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Daratumumab/rHuPH20
Study Phase: Phase 3
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Enrollment Status: Completed
Publish Date: August 19, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: August 06, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: ProTmune Ex Vivo Programmed Mobilized Peripheral Cells
Study Phase: Phase 1/Phase 2
Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes
Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Biological, Drug
Study Drugs: Mycophenolate Mofetil, Sargramostim, Filgrastim
Study Phase: Phase 2
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: March 17, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
View 7 Less Clinical Trials

40 Total Publications

Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation.
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation.
Journal: JACC. CardioOncology
Published: February 16, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Harold M. Chung
Hematology | Oncology | Transplant Surgery
Expertise in
19
conditions
Dr. Harold M. Chung
Hematology | Oncology | Transplant Surgery
1250 E Marshall St, Internal Medicine, 
Richmond, VA 
 (0.1 miles away)
804-828-9723
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Harold Chung is a Hematologist and an Oncologist in Richmond, Virginia. Dr. Chung is highly rated in 19 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Chung is currently accepting new patients.

Expertise in
44
conditions
Dr. Andrew Poklepovic
Hematology | Oncology
Expertise in
44
conditions
Dr. Andrew Poklepovic
Hematology | Oncology

Mcv Associated Physicians

1001 E Leigh St, 
Richmond, VA 
 (2.0 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Poklepovic is a Hematologist and an Oncologist in Richmond, Virginia. Dr. Poklepovic is highly rated in 44 conditions, according to our data. His top areas of expertise are Melanoma, Angiosarcoma, Merkel Cell Carcinoma, Adult Soft Tissue Sarcoma, and Bone Marrow Aspiration.

Expertise in
30
conditions
Dr. Baldeep M. Wirk
Hematology Oncology | Transplant Surgery | Hematology
Expertise in
30
conditions
Dr. Baldeep M. Wirk
Hematology Oncology | Transplant Surgery | Hematology

Mcv Associated Physicians

1300 E Marshall St, 
Richmond, VA 
 (0.1 miles away)
804-828-0450
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Baldeep Wirk is a Hematologist Oncology specialist and a Transplant Surgeon in Richmond, Virginia. Dr. Wirk is highly rated in 30 conditions, according to our data. Her top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Marginal Zone Lymphoma (MZL), Bone Marrow Transplant, and Bone Graft. Dr. Wirk is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccarty's expertise for a condition
ConditionClose
    View All 11 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile